Sandra Leung, executive president and general counsel at Bristol-Myers Squibb, plans to retire from her position during 2025.
According to a company spokesperson, Cari Gallman will be her successor with the transition expected to occur later this year. Gallman’s new title will be executive vice president, general counsel and chief policy officer. An SEC filing from the biopharmaceutical firm states that Leung is expected to remain with Bristol-Myers Squibb to help with the transition of her duties.
Leung’s LinkedIn profile states that she took on her current role in 2014, having previously been senior vice president, general counsel and corporate secretary with the firm. She joined Bristol-Myers Squibb in 1992 as a staff attorney in the litigation department.
Before moving in-house Leung was a prosecutor in the Manhattan District Attorney’s Office.
Gallman is at present executive vice president for corporate affairs at Bristol-Myers Squibb, a role in which she is responsible for strategic communications, government relations and policy, corporate social responsibility, corporate marketing and brand reputation and patient advocacy. According to her LinkedIn profile, she has been with the company since 2015 in roles including senior vice president and chief compliance and ethics officer and earlier vice president and assistant general counsel for oncology.
Before joining the company, she was a litigation associate with Debevoise & Plimpton.
The spokesperson says in a statement: ‘Sandy’s leadership has been instrumental in shaping Bristol-Myers Squibb into the innovative and patient-focused organization it is today. The company is grateful for her leadership.’
Ben Maiden
Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...
